We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

By LabMedica International staff writers
Posted on 25 Jul 2025

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. More...

However, obtaining PRP traditionally requires expensive centrifugation techniques, may prematurely activate platelets, and often reduce their therapeutic effectiveness. These methods also involve complex equipment and handling that limit their use in low-resource or point-of-care settings. To overcome these challenges, researchers have developed a novel method that separates PRP directly from blood without requiring centrifugation. The new approach yields high-quality, minimally activated platelets, offering a cost-effective and portable alternative to existing methods.

This solution, developed at the University of the Basque Country (Leioa, Spain), is a disposable, low-cost device based on gravity sedimentation, a process where denser particles settle under gravity. Unlike traditional centrifuge-based equipment, the system is made from laser-cut acrylic sheets and special adhesives, making it affordable and easy to manufacture. This innovation is the result of over a decade of research into Lab-on-a-Chip technologies—compact systems that replicate laboratory functions on a single microdevice. During their studies, the team observed that plasma separated in these devices was rich in low-activated platelets, prompting a redesign for therapeutic purposes. The device can extract about 300 microliters of PRP from 1 milliliter of blood in 40 minutes and can be scaled for different blood volumes.

The system was tested and validated through performance metrics, including platelet activation levels and blood component separation. Compared to traditional methods, platelet activation was significantly reduced to 8.2% from 31%, while maintaining the mean platelet volume crucial for PRP efficacy. It also eliminated 98% of red blood cells and 96% of white blood cells. The findings, published in Lab on a Chip, demonstrate the device’s potential for use in personalized treatments, resource-limited clinics, and home healthcare.

Related Links:
University of the Basque Country


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
Rapid Molecular Testing Device
FlashDetect Flash10
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.